Novartis

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Mon, 11/5/18 - 11:53 am
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Sat, 11/3/18 - 12:39 pm
Novartis
Sandoz
rituximab
biosimilars
Roche
NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?
Xtalks
Thu, 11/1/18 - 07:13 pm
Pfizer
Novartis
NASH
Novartis wins US nod for Humira biosimilar, but focus now on Europe
Biopharma Dive
Wed, 10/31/18 - 07:09 pm
Novartis
Hyrimoz
biosimilars
Humira
AbbVie
FDA
Novartis May Beat Ironwood Pharmaceuticals to the Punch
Motley Fool
Tue, 10/30/18 - 11:17 pm
Novartis
crizanlizumab
sickle cell disease
Ironwood Pharmaceuticals
IW-1701
Novartis Cuts 20% of Drug-Research Projects After Review
Bloomberg
Tue, 10/30/18 - 12:12 pm
Novartis
R&D
drug development
Big Pharma rivals Pfizer and Novartis team up on NASH combo targets
Fierce Biotech
Mon, 10/29/18 - 11:50 am
Pfizer
Novartis
NASH
drug development
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Mon, 10/29/18 - 10:27 am
Roche
Genentech
Regeneron
Novartis
Eylea
faricimab
wet-AMD
This Big Pharma Bet Isn't Paying Off Yet
Motley Fool
Sun, 10/28/18 - 07:42 pm
Big Pharma
biosimilars
Novartis
Amgen
Merck
Pfizer
Biogen
Endocyte deal showcases Novartis' complex manufacturing juggling act
Biopharma Dive
Thu, 10/25/18 - 11:25 pm
Novartis
Endocyte
earnings
drug manufacturing
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
Thu, 10/25/18 - 09:52 am
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
Thu, 10/25/18 - 09:35 am
Incyte
graft vs host disease
Novartis
Jakafi
Being there: Amgen and Novartis roll out first ad campaign for migraine drug Aimovig
Fierce Pharma
Tue, 10/23/18 - 01:28 pm
Novartis
Amgen
Aimovig
DTC ads
television ads
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Mon, 10/22/18 - 05:17 pm
Europe
AbbVie
Humira
Amgen
Samsung Bioepis
Mylan Labs
Novartis
Sandoz
Fresenius Kabi
Boehringer Ingelheim
Novartis in constant evolution: new large investment in startup
GoinPharma
Sun, 10/21/18 - 11:31 pm
Gamida Cell
IPOs
Novartis
NiCord
Novartis wants to blaze a trail in breast cancer with PIK3 drug
Pharmaforum
Sun, 10/21/18 - 11:26 pm
Novartis
clinical trials
alpelisib
breast cancer
ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients
Fierce Biotech
Sat, 10/20/18 - 11:10 pm
Europe
Novartis
ESMO
AstraZeneca
breast cancer
BYL719
NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir
Fierce Pharma
Sat, 10/20/18 - 10:37 pm
Lilly
Verzenio
breast cancer
Pfizer
Ibrance
Novartis
Kisqali
NICE
Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Biopharma Dive
Thu, 10/18/18 - 01:08 pm
Novartis
earnings
M&A
Endocyte
Are all new sales created equal?
EP Vantage
Wed, 10/17/18 - 10:28 am
GSK
Pfizer
Novartis

Pages